Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending December 6, 2012. The report details a specific share repurchase transaction executed in accordance with shareholder authority granted at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 690,100 Ordinary Shares of 25 pence each.
- Purchase Date: December 6, 2012.
- Price Range: Highest price paid was 1,356.0 pence per share; lowest price paid was 1,339.0 pence per share.
- Treasury Holdings (Settled): 490,140,427 shares (9.08% of total issued share capital).
- Treasury Holdings (Including Unsettled): 491,521,327 shares (10.02% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,907,678,744 shares.
Material Changes
The primary material change is the reduction of outstanding shares through the purchase of 690,100 shares for treasury. Consequently, the percentage of shares held in treasury increased to 10.02% of total voting rights when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance disclosure under the Financial Services Authority's Disclosure and Transparency Rules regarding share ownership changes.
Investor Verification Checklist
- Verify the total number of shares held in treasury (490,140,427 settled) against the company's latest capitalization table.
- Confirm the calculation of total voting rights (10.02% held in treasury including unsettled shares).
- Check the denominator for shareholder notification thresholds (4,907,678,744 shares in issue).
- Review the price paid (1,339.0 to 1,356.0 pence) against the market price on December 6, 2012.